Boston MA 软组织肉瘤临床试验
17项针对 软组织肉瘤的研究正在 Boston及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Anti-GD2 ADC M3554 in Advanced Solid Tumors
招募中1 期
- Dana-Farber Cancer Institute, Boston
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
招募中1 期
- Dana-Farber Cancer Institute, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
招募中
- Dana-Farber Cancer Institute, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
招募中2 期
- Dana-Farber Cancer Institute - Oncology Department, Boston
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
招募中1/2 期
- Dana Farber Cancer Institute, Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
招募中1/2 期
- Dana Farber Cancer Institute., Boston
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
招募中1/2 期
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
招募中1 期
- Dana-Farber Cancer Institute, Boston
Serial MRI Scans During Radiation Therapy
招募中
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention
招募中
- Boston Children's Hospital, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
招募中1/2 期
- Dana Farber Cancer Institute, Boston
Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
招募中观察性研究
- Brigham and Women's Hospital, Boston
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
招募中观察性研究
- Dana-Farber Cancer Institute, Boston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
招募中1/2 期
- Massachusetts General Hospital,, Boston
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
招募中1/2 期
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
招募中1/2 期
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
REtroperitoneal SArcoma Registry: an International Prospective Initiative
招募中观察性研究
- Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston
其他城市的 软组织肉瘤试验
- Houston, TX32 项研究
- New York City, NY20 项研究
- Los Angeles, CA13 项研究
- St. Louis, MO12 项研究
- Columbus, OH12 项研究
- Washington, DC11 项研究
- Memphis, TN10 项研究
- Philadelphia, PA9 项研究
- Aurora, CO8 项研究
- Nashville, TN8 项研究
- Durham, NC8 项研究
- Queens, NY8 项研究
Boston的其他研究
- 乳腺癌110 项研究
- 癌症（所有类型）90 项研究
- 非小细胞肺癌87 项研究
- 肺癌63 项研究
- 结直肠癌62 项研究
- 卵巢癌62 项研究
- 转移性癌症61 项研究
- 前列腺癌56 项研究
- 子宫内膜癌51 项研究
- 抑郁症50 项研究
- 心力衰竭46 项研究
- 多发性骨髓瘤45 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。